The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Abbvie; Janssen; Karyopharm Therapeutics; Kite/Gilead; MorphoSys; Novartis; TeneoBio
Speakers' Bureau - AstraZeneca; BeiGene; Epizyme; MorphoSys
Research Funding - Merck (Inst); Merck (Inst)
Efficacy and safety of tisagenlecleucel (Tisa-cel) in adult patients (Pts) with relapsed/refractory follicular lymphoma (r/r FL): Primary analysis of the phase 2 Elara trial.
 
Stephen J. Schuster
Consulting or Advisory Role - Abbvie; Acerta Pharma/AstraZeneca; Alimera Sciences; BeiGene; Celgene; Genentech/Roche; Juno Therapeutics; Loxo; Nordic Nanovector; Novartis; Tessa Therapeutics
Research Funding - Abbvie (Inst); Adaptive Biotechnologies (Inst); Celgene (Inst); DTRM (Inst); Genentech/Roche (Inst); Incyte (Inst); Juno Therapeutics (Inst); Merck (Inst); Novartis (Inst); Pharmacyclics (Inst); TG Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Patent Combination Therapies of CAR and PD-1 Inhibitors (via University of Pennsylvania with royalties to Novartis)
 
Michael J. Dickinson
Honoraria - Amgen; Bristol-Myers Squibb; Bristol-Myers Squibb; Janssen; MSD; Novartis; Roche
Consulting or Advisory Role - Bristol-Myers Squibb; Gilead Sciences; Janssen; Novartis; Roche (I)
Speakers' Bureau - Novartis
Research Funding - Celgene (Inst); MSD (Inst); Novartis (Inst); Roche (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Roche
 
Martin H. Dreyling
Consulting or Advisory Role - Acerta Pharma/AstraZeneca; Bayer/Vital; Beigene; Celgene/Jazz; Gilead Sciences; Janssen-Cilag; Novartis; Roche
Speakers' Bureau - Bayer Health; Celgene; Gilead Sciences; Janssen-Cilag; Roche Pharma AG
Research Funding - Abbvie (Inst); Celgene (Inst); Janssen-Cilag (Inst); Roche Pharma AG (Inst)
Travel, Accommodations, Expenses - Celgene; Janssen-Cilag; Roche Pharma AG
 
Joaquín Martínez
Stock and Other Ownership Interests - Altum Sequencing
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; GlaxoSmithKline; Incyte; Janssen; Novartis
Speakers' Bureau - Astellas Pharma; Bristol-Myers Squibb; GlaxoSmithKline; Incyte; Janssen; Novartis
Research Funding - Bristol-Myers Squibb; Roche
 
Arne Kolstad
Consulting or Advisory Role - Nordic Nanovector
Research Funding - Merck; Nordic Nanovector
Travel, Accommodations, Expenses - Nordic Nanovector
 
Jason Paul Butler
Consulting or Advisory Role - Novartis
Speakers' Bureau - Novartis
 
Monalisa Ghosh
Research Funding - Bristol-Myers Squibb; Novartis
 
Leslie Popplewell
Honoraria - pfizer; Roche
Travel, Accommodations, Expenses - Novartis
 
Julio C. Chavez
No Relationships to Disclose
 
Emmanuel Bachy
Honoraria - Celgene; Gilead Sciences; Janssen; Novartis; Roche
Consulting or Advisory Role - Incyte; Roche
Research Funding - Amgen; Takeda
 
Koji Kato
Honoraria - Bristol-Myers Squibb; Celgene; Dainippon-Sumitomo; Janssen; Kyowa Kirin International; MSD; Mundipharma; Ono Pharmaceutical; Takeda
Consulting or Advisory Role - Abbvie; AstraZeneca; Celgene; Chugai Pharma; Daiichi Sankyo; Eisai; Janssen; Novartis
Research Funding - Abbvie; Celgene; Chugai Pharma; Daiichi Sankyo; Eisai; Janssen; Kyowa Kirin International; Novartis; Novartis; Ono Pharmaceutical; Takeda
 
Hideo Harigae
Honoraria - Bristol-Myers Squibb; Chugai Pharma; Janssen; Novartis
Research Funding - Astellas Pharma
 
Marie José Kersten
Honoraria - Kite, a Gilead company; Novartis; Roche
Consulting or Advisory Role - Kite, a Gilead Company; Miltenyi Biotec (Inst); Novartis; Takeda (Inst)
Research Funding - Kite, a Gilead company (Inst)
Travel, Accommodations, Expenses - Celgene; Kite, a Gilead Company; Novartis; Roche
 
Charalambos Andreadis
Employment - Genentech (I)
Stock and Other Ownership Interests - Roche/Genentech (I)
Consulting or Advisory Role - Atara Biotherapeutics; Epizyme; Gilead Sciences; Incyte; Karyopharm Therapeutics; Kite, a Gilead company; TG therapeutics
Research Funding - Amgen; Celgene; GlaxoSmithKline; Juno Therapeutics; Merck; Novartis
Travel, Accommodations, Expenses - Gilead Sciences; Kite, a Gilead company
 
Peter A. Riedell
Honoraria - Novartis
Consulting or Advisory Role - Bayer; BeiGene; Bristol-Myers Squibb/Celgene; Karyopharm Therapeutics; Kite, a Gilead company; Novartis; Takeda; Verastem
Speakers' Bureau - Bayer; Kite, a Gilead company
Research Funding - Bristol-Myers Squibb/Celgene; Calibr; Kite, a Gilead company; MorphoSys; Novartis
 
Ahmed M. Abdelhady
Employment - Novartis Pharmaceuticals UK Ltd.
 
Aiesha Zia
Employment - Novartis Pharmaceuticals UK Ltd.
 
Mony Chenda Morisse
Employment - Novartis
 
Nathan Hale Fowler
Consulting or Advisory Role - Bayer; Celgene; Novartis; Roche/Genentech; TG Therapeutics; Verastem
Research Funding - Abbvie; BeiGene; Celgene; Gilead Sciences; Novartis; Roche; TG Therapeutics
 
Catherine Thieblemont
Honoraria - Abbvie; Bayer; Celgene; Gilead Sciences; Incyte; Janssen; Novartis; Roche
Research Funding - Roche
Travel, Accommodations, Expenses - Janssen-Cilag; Kite/Gilead; Novartis; Roche